{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:16:38Z","timestamp":1785568598472,"version":"3.56.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH109-9R23"],"award-info":[{"award-number":["KMUH109-9R23"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST109-2314-B-037-127"],"award-info":[{"award-number":["MOST109-2314-B-037-127"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,5,18]]},"abstract":"<jats:p>\n            The Clinical and Laboratory Standards Institute (CLSI) revised the fluoroquinolone MIC breakpoints for\n            <jats:italic>Enterobacterales<\/jats:italic>\n            in 2019, based on pharmacokinetic\/pharmacodynamic analyses. However, clinical evidence supporting these breakpoint revisions is limited.\n          <\/jats:p>","DOI":"10.1128\/aac.00074-21","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T12:36:33Z","timestamp":1616848593000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with\n            <i>Enterobacterales<\/i>\n            Bacteremia"],"prefix":"10.1128","volume":"65","author":[{"given":"Ho-Yin","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"},{"name":"College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Pin","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tun-Chieh","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"},{"name":"Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"},{"name":"Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Pin","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Public Health and Environmental Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-4077","authenticated-orcid":true,"given":"Shang-Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"},{"name":"College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363240-00008"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/319370"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.04.007"},{"key":"e_1_3_3_5_2","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 29th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"29"},{"key":"e_1_3_3_6_2","volume-title":"Fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. CLSI rationale document MR02.","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. CLSI rationale document MR02. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00580-08"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-017-0202-4"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.199"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/383320"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1672-1680.2003"},{"key":"e_1_3_3_12_2","unstructured":"The National Antimicrobial Susceptibility Testing Committee for the United States. 2018. Quinolone in vitro susceptibility test interpretive criteria evaluations. Version 1.3. http:\/\/www.uscast.org. Accessed 10 August 2020."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-19"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-6804-3"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/514623"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.669"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9040189"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2018.08.011"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00663-12"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm279"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540110080629"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C419"},{"key":"e_1_3_3_23_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. http:\/\/www.eucast.org. Accessed 10 August 2020."},{"key":"e_1_3_3_24_2","unstructured":"U.S. Food and Drug Administration. 2020. FDA rationale for recognition decision: levofloxacin. http:\/\/www.fda.gov\/drugs\/development-resources\/fda-rationale-recognition-decision-levofloxacin. Accessed 17 August 2020."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.07.027"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02697-14"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815Y.0000000033"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-73-3-387"},{"key":"e_1_3_3_29_2","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 28th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"28"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis916"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709751"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-1-200401060-00008"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2008.03.002"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00074-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00074-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:28:22Z","timestamp":1645486102000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00074-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,5,18]]}},"alternative-id":["10.1128\/AAC.00074-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00074-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"2021-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00074-21"}}